İçeriğe geç
akaturk Akademik ölçüm
Giriş yap Kayıt ol

OpenAlex konusu

Chemotherapy-induced cardiotoxicity and mitigation

Bu sayfa OpenAlex konu etiketine göre çalışmaları ve o konuda görünen akademisyenleri listeler. YÖKSİS temel alan / yan dal değildir.

OpenAlex 2.229 eser 42 yazar konusu

Çalışmalar

2.229 eser

  1. Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity 2023
    YÖKSİS SJR Q1 JCR Q2 OpenAlex üst %1 OpenAlex 100.0%

    Doxorubicin (DOX) constitutes the major constituent of anti-cancer treatment regimens currently in clinical use. However, the precise mechanisms of DOX's action are not fully understood. Emerging evidence points to the pleiotropic anticancer activity of DOX, including its contribution to DNA damage, reactive oxygen sp…

  2. Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy 2006
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %10 OpenAlex 98.4%

    Özet henüz yok.

  3. Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy 2006
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %10 OpenAlex 98.4%

    Özet henüz yok.

  4. Protective Effects of Carvedilol Against Anthracycline Induced Cardiomyopathy 2006
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %10 OpenAlex 98.4%

    Özet henüz yok.

  5. Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy 2006
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %10 OpenAlex 98.4%

    Özet henüz yok.

  6. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) 2022
    YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %1 OpenAlex 100.0%

    SCOPUS: ar.j

  7. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control study 2013
    YÖKSİS SJR Q2 JCR Q1 OpenAlex üst %10 OpenAlex 98.8%

    Özet henüz yok.

  8. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control study 2013
    YÖKSİS SJR Q2 JCR Q1 OpenAlex üst %10 OpenAlex 98.8%

    Özet henüz yok.

  9. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control study 2013
    YÖKSİS SJR Q2 JCR Q1 OpenAlex üst %10 OpenAlex 98.8%

    Özet henüz yok.

  10. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control study 2013
    YÖKSİS SJR Q2 JCR Q1 OpenAlex üst %10 OpenAlex 98.8%

    Özet henüz yok.

  11. TAXUS III Trial 2003
    OpenAlex üst %1 OpenAlex 100.0%

    BACKGROUND: The first clinical study of paclitaxel-eluting stent for de novo lesions showed promising results. We performed the TAXUS III trial to evaluate the feasibility and safety of paclitaxel-eluting stent for the treatment of in-stent restenosis (ISR). METHODS AND RESULTS: The TAXUS III trial was a single-arm, 2…

  12. Protective effect of lycopene on adriamycin induced cardiotoxicity and nephrotoxicity 2006
    YÖKSİS OpenAlex üst %10 OpenAlex 93.0%

    Özet henüz yok.

Akademisyenler

42 akademisyen